Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
出版年份 2012 全文链接
标题
Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
作者
关键词
-
出版物
Annual Review of Medicine
Volume 64, Issue 1, Pages 1-13
出版商
Annual Reviews
发表日期
2012-10-01
DOI
10.1146/annurev-med-121211-091605
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: Apreliminary report.
- (2017) E. Efstathiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
- (2017) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC).
- (2017) Joel Robert Eisner et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- MDV3100 for the treatment of prostate cancer
- (2012) Deborah Mukherji et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
- (2011) M. S. Darshan et al. CANCER RESEARCH
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- (2011) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
- (2011) Simon Pacey et al. CLINICAL CANCER RESEARCH
- Molecular genetics of prostate cancer: emerging appreciation of genetic complexity
- (2011) Christopher E Barbieri et al. HISTOPATHOLOGY
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice
- (2011) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
- (2011) Eleni Efstathiou et al. JOURNAL OF CLINICAL ONCOLOGY
- The changing therapeutic landscape of castration-resistant prostate cancer
- (2011) Timothy A. Yap et al. Nature Reviews Clinical Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
- (2011) Xiaotun Zhang et al. PLoS One
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
- (2009) L. Gan et al. CANCER RESEARCH
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative Activation of Disseminated Tumor Cells in Bone Marrow of Patients With Prostate Cancer
- (2009) Dorothea Weckermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
- (2008) D. Olmos et al. ANNALS OF ONCOLOGY
- Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
- (2008) G Attard et al. BRITISH JOURNAL OF CANCER
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
- (2008) J. A. Locke et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro
- (2008) A. Schayowitz et al. MOLECULAR CANCER THERAPEUTICS
- 17 -Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response
- (2008) R. D. Bruno et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now